A phase I dose-escalation and expansion study of HBM4003, an anti-CTLA-4 heavy chain only monoclonal antibody, in patients with advanced solid tumors.

Citation

• Gu, S., de Souza, P. L., Shi, Y., Han, W., Luo, S., Chen, J., . . . Chen, X. (2022). A phase I dose-escalation and expansion study of HBM4003, an anti-CTLA-4 heavy chain only monoclonal antibody, in patients with advanced solid tumors.. Journal of Clinical Oncology, 40(16_suppl), 2641. doi:10.1200/jco.2022.40.16_suppl.2641

Digital Object Identifier (doi)

• 10.1200/jco.2022.40.16_suppl.2641

Web Of Science Accession Number

Start Page

• 2641

End Page

• 2641

Volume

• 40

Issue

• 16_suppl

Abstract

UOW Authors

•   De Souza, Paul (external author)

Publication Date

• 2022

Publisher

• American Society of Clinical Oncology (ASCO) 

Published In

• Journal of Clinical Oncology  Journal

Citation

• Gu, S., de Souza, P. L., Shi, Y., Han, W., Luo, S., Chen, J., . . . Chen, X. (2022). A phase I dose-escalation and expansion study of HBM4003, an anti-CTLA-4 heavy chain only monoclonal antibody, in patients with advanced solid tumors.. Journal of Clinical Oncology, 40(16_suppl), 2641. doi:10.1200/jco.2022.40.16_suppl.2641

Digital Object Identifier (doi)

• 10.1200/jco.2022.40.16_suppl.2641

Web Of Science Accession Number

Start Page

• 2641

End Page

• 2641

Volume

• 40

Issue

• 16_suppl